ANI Pharmaceuticals (ANIP) closed at $71.52 on Oct 6, 2026, down 1.5% on the day. The stock is up 0.4% over the past month, down 15.6% over three months, down 9.4% year to date and down 20.2% over the past year. It trades 25.9% below its 52-week high of $96.57 and 2.8% above its 52-week low of $69.58. The close sits below its 50-day moving average ($75.07) and below its 200-day moving average ($78.42).
No — the Oct 6, 2026 close of $71.52 is 8.8% below the 200-day average of $78.42.
ANIP closed 25.9% below its 52-week high of $96.57.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
